Teva Pharmaceutical Industries Ltd. could face earlier competition for its 40 mg/mL three-times-a-week dosage of Copaxone (glatiramer) now that the US Patent and Trademark Office's Patent Trial and Appeal Board has determined that two patents covering the product are not patentable.
On Aug. 24, PTAB issued a pair of final written decisions on inter partes review petitions challenging the patents on...




